Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lyell ImmunopharmaLYEL +1.47%55 EBITDA Margin % is -2,096,450.00% as of Mar. 2026. GuruFocus rates LYEL with a GF Score™ of 55/100 and a GF Value™ of $5.26 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 940 Biotechnology companies, Lyell Immunopharma ranks worse than 99.57% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lyell Immunopharma's EBITDA for the
three
months ended in Mar. 2026 was $-41.93 Mil. Lyell Immunopharma's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Lyell Immunopharma's EBITDA margin for the quarter that ended in Mar. 2026 was -2,096,450.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Lyell Immunopharma EBITDA Margin % Related Terms
Lyell Immunopharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Lyell Immunopharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LYEL vs ALXO, ARMP, NAGE: EBITDA Margin % Comparison
For the Biotechnology subindustry, Lyell Immunopharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyell Immunopharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Lyell Immunopharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a EBITDA Margin % of -2,096,450.00% mean?
Lyell Immunopharma (LYEL) has a EBITDA Margin % of -2,096,450.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lyell Immunopharma and its competitors. According to the industry distribution chart, Lyell Immunopharma ranks #936 out of 940 companies in the Biotechnology industry, placing it in the top 99.6%.
Is Lyell Immunopharma's EBITDA Margin % too high?
Lyell Immunopharma's current EBITDA Margin % is -2,096,450.00%. Based on the distribution chart, Lyell Immunopharma ranks #936 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lyell Immunopharma has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lyell Immunopharma's EBITDA Margin % compare to ALXO and ARMP?
According to the Biotechnology industry distribution chart, Lyell Immunopharma ranks #936 out of 940 companies for EBITDA Margin %. This places Lyell Immunopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lyell Immunopharma and its competitors. Lyell Immunopharma's current EBITDA Margin % is -2,096,450.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyell Immunopharma stock overvalued right now?
Based on GuruFocus' analysis, Lyell Immunopharma (LYEL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.26, compared to a current price of $13.19 — trading 150.8% above its estimated fair value. The current EBITDA Margin % is -2,096,450.00%. Lyell Immunopharma's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Lyell Immunopharma (LYEL), the current EBITDA Margin % is -2,096,450.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyell Immunopharma (LYEL) Overvalued in 2026?
Based on GuruFocus' analysis, Lyell Immunopharma stock appears to be overvalued.
The current stock price of $13.19 is trading 150.8% above its estimated GF Value™ of $5.26.
GuruFocus considers Lyell Immunopharma to be Significantly Overvalued.
Key valuation signals for LYEL:
EBITDA Margin %: -2,096,450.00%
GF Value™: $5.26 vs. price of $13.19 (150.8% above fair value)
No single metric tells the full story. See the LYEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
55GF Score
Get the complete analysis for LYEL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LYEL has been successfully added to your 
